國家衛生研究院 NHRI:Item 3990099045/7569

NHRI > Institute of Biotechnology and Pharmaceutical Research > Hsing-Pang Hsieh > Conference Papers/Meeting Abstract > Item 3990099045/7569

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7569

Title:	Design, synthesis, and SAR studies of duel FLT-3 and Aurora kinase inhibitors
Authors:	Hsieh, HP;Shiao, HY;Lin, WH;Hsu, JTA;Chao, YS
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	Aurora kinase and FMS-like Tyrosine Receptor 3 (FLT3) was found to associate with various cancers, including breast cancers, colorectal cancers, AML and so on. There are several Aurora kinase inhibitors and FLT3 inhibitors was developed and under clinical investigation. And no Aurora kinase inhibitors or FLT3 inhibitors currently approved for the treatment of cancers still.[p]We synthesized more than 1000 compounds mainly targeted at Aurora kinase. BPR1K871, a novel, potent, small-molecule inhibitor of multiple kinase showed potent in vitro activities for Aurora kinase A (IC50: 50 nM), FLT-3 (IC50: 29 nM) and at least other 17 kinases with low IC50 activities (nano molar range). In cell-based assay, BPR1K871also demonstrated its excellent anticancer activities (HCT116: 117 nM, MOLM-13: 2 nM, MIA Paca-2: 9 nM, Colo205: 33 nM). In the MOLM-13 xenograft animal studies, BPR1K871 suppressed tumor growth up to 98% at 3 mg/kg once a day for 10-day treatment by IV administration. The body weight loss is less than 5% during the dosing period. This non-clinical profile of BPR1K871 supports the further pre-clinical development.
Date:	2012-03-25
Relation:	Abstracts of Papers - American Chemical Society. 2012 Mar 25;243:Article number 48-MEDI.
Link to:	http://abstracts.acs.org/chem/243nm/program/view.php?pub_num=48&par=MEDI
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000324503201706
Appears in Collections:	[Hsing-Pang Hsieh] Conference Papers/Meeting Abstract [John Tsu-An Hsu] Conference Papers/Meeting Abstract [Yu-Sheng Chao(2002-2013)] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI000324503201706.pdf		81Kb	Adobe PDF	549	View/Open

Loading...